Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7 Ovarian Neoplasms 4 Neoplasm Metastasis 3 Endometrial Neoplasms 3 Stomach Neoplasms 2 Prostatic Neoplasms 2 Multiple Myeloma 2 Mouth Neoplasms 2 Lymphoma 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

Oxaliplatin 19 pembrolizumab 13 Fluorouracil 12 Leucovorin 11 Capecitabine 11 Paclitaxel 10 Gemcitabine 8 Docetaxel 8 zolbetuximab 6 cemiplimab 6 Cisplatin 6 Albumin-Bound Paclitaxel 6 durvalumab 5 Ramucirumab 5 Radiotherapy 5 Irinotecan 4 Cyclophosphamide 4 130-nm albumin-bound paclitaxel 4 trastuzumab deruxtecan 3 tislelizumab 3 lenvatinib 3 enzalutamide 3 darolutamide 3 atezolizumab 3 Trastuzumab 3 Taxes 3 S 1 (combination) 3 Radiosurgery 3 Pemetrexed 3 Nivolumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × ipatasertib × 1 year × Clear all

NCT04739202 2026-06-09

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡